Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Takeda’s Uloric (febuxostat) ended a forty-year drought for new gout treatments when FDA approved the oral drug for chronic disease on Feb. 13, but a pipeline stocked with new drugs holds the promise of a shorter wait for the next gout therapy.
You may also be interested in...
AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk
Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid
PHILADEPHIA – Though Takeda's gout therapy Uloric (febuxostat) has broken a 40-year dry spell in the market, physicians and researchers are hoping more drugs will be approved that can reduce serum uric acid well below the standard 6 mg/dL benchmark. Safety, though, could be a hang-up.